Skip to main content
. 2019 Nov 15;35(3):714–722. doi: 10.3904/kjim.2018.404

Figure 1.

Figure 1.

Incidence of teicoplanin adverse drug reactions (ADRs) according to history of vancomycin hypersensitivity. The incidences of teicoplanin ADRs were 3.7% (1/27) in patients with no history of vancomycin administration, 6.0% (4/67) in patients without hypersensitivity reaction after vancomycin administration, and 25.2% (53/210) in patients who previously experienced vancomycin hypersensitivity excluding acute kidney injury. a p < 0.01, b p < 0.001.